CD19-directed chimeric antigen receptor T cell therapy (CART) has transformed treatment of relapsed or refractory (r/r) large B cell lymphoma (LBCL); however, organ-specific response patterns and depth of response (DoR) remain insufficiently characterized. This study evaluated organ-specific imaging response and the im...
M. Kassube, P. Achhammer, Philipp Linden et al.· Cancer Immunology and Immuno...· 0 citations
Clonal hematopoiesis of indeterminate potential (CHIP) has been well-characterized in patients receiving chemotherapy and hematopoietic cell transplantation. However, its immunologic relevance and potential role in modulating chimeric antigen receptor T-cell (CAR-T) therapy-related toxicities, inflammation, and clinica...
Giulia Rappa, F. Ziemann, Kieron White et al.· Leukemia· 0 citations
Post-CAR-T t-MN carries an independent survival disadvantage not explained by TP53 clone burden; allogeneic HCT remains the only potentially curative option.
Michael D. Jain, Alaa Ali, Jaime Roman Diaz et al.· Blood Advances· 0 citations
Findings indicate that post-Blina CD8+ T-cell exhaustion is associated with resistance and it is shaped by both reduced ZNF683-dependent cytotoxic programming in CD8+ TEM and an immunosuppressive milieu.
Francesco Corrado, V. Blumenberg, Maryam Kazerani et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.